Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $10.7 billion.

  • Gsk's Receivables - Net rose 1161.98% to $10.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.7 billion, marking a year-over-year increase of 1161.98%. This contributed to the annual value of $8.7 billion for FY2024, which is 487.0% down from last year.
  • Per Gsk's latest filing, its Receivables - Net stood at $10.7 billion for Q3 2025, which was up 1161.98% from $9.8 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Receivables - Net ranged from a high of $10.8 billion in Q3 2023 and a low of $3.2 billion during Q1 2022
  • In the last 5 years, Gsk's Receivables - Net had a median value of $9.0 billion in 2021 and averaged $9.0 billion.
  • Per our database at Business Quant, Gsk's Receivables - Net tumbled by 6380.08% in 2022 and then skyrocketed by 15630.28% in 2023.
  • Over the past 5 years, Gsk's Receivables - Net (Quarter) stood at $10.6 billion in 2021, then fell by 21.92% to $8.3 billion in 2022, then increased by 10.8% to $9.2 billion in 2023, then dropped by 4.28% to $8.8 billion in 2024, then rose by 22.04% to $10.7 billion in 2025.
  • Its Receivables - Net stands at $10.7 billion for Q3 2025, versus $9.8 billion for Q2 2025 and $8.9 billion for Q1 2025.